Santaris Pharma's HIF-1 alpha antagonist begins second phase 1 study against solid tumours and lymphoma
Enzon Pharmaceuticals, Inc. has initiated a second clinical study of EZN-2968 to evaluate additional dosing schedule
06-Nov-2007 -
Santaris Pharma A/S announced the initiation of an open-label, non-randomized Phase 1 study with its HIF-1 alpha antagonist (EZN-2968) licensed outside Europe in 2006 to Enzon Pharmaceuticals, Inc. USA. The study is designed to evaluate the safety, tolerability, and pharmacokinetics of the HIF-1 ...
angiogenesis
apoptosis
dosing
+3